Table 4.

Recovery time length association with early/late/no drug use

	Drug use	Beta (95% CI)	P-value
Arbidol	Early use vs No use	− 5.2 (− 7.5, − 3.0)	4.0E−06
	Late use vs No use	1.4 (− 0.1, 2.9)	0.074
	Overall use vs No use	− 0.1 (− 1.8, 1.6)	0.91
Ribavirin	Early use vs No use	− 0.3 (− 2.2, 1.59)	0.75
	Late use vs No use	3.0 (1.1, 4.8)	0.0018
	Overall use vs No use	2.1 (0.5, 3.7)	0.01
IFN-α	Early use vs No use	− 0.2 (− 2.0, 1.6)	0.82
	Late use vs No use	2.2 (− 0.1, 4.4)	0.06
	Overall use vs No use	1.4 (− 0.6, 3.4)	0.17
Lopinavir–ritonavir	Early use vs No use	4.7 (3.1, 6.2)	1.8E−08
	Late use vs No use	7.5 (5.4, 9.6)	1.7E−11
	Overall use vs No use	4.1 (2.3, 5.9)	1.4E−05

Association test between patients’ recovery time length against where early drug use or not; late drug use or not. Multivariate linear regression model was used and risk factors and confounding factors were adjusted